Latest Stem cell treatments Stories
Frank Farmer has come on board with World Stem Cell Institute, Inc. after his son Kell's stem cell treatment and was amazed at his son's progress. Frank has become an advocate for the use of Stem Cell Treatment(SCT) for other qualified children with ASD along with promoting and aiding World Stem Cell Institute, Inc. to complete clinical trials for preemie babies and other diseases. Tampa, FL (PRWEB) December 27, 2012 Frank Farmer is a business owner of 15 years specializing in...
Dr. Scott Brandt of ThriveMD specializes in minimally invasive stem cell therapy to repair traumatic joint injuries and bioidentical hormone replacement therapy for men and women interested in optimizing their health. Edwards, CO (PRWEB) December 24, 2012 ThriveMD is a new medical practice located in Edwards, Colorado that offers regenerative and restorative medicine. Dr. Scott Brandt, Medical Director for ThriveMD, specializes in minimally invasive stem cell therapies to repair traumatic...
WINNIPEG, Manitoba, Dec. 11, 2012 /PRNewswire/ -- Doug Broeska, Ph.D., CEO of Regenetek Research Inc., an international medical research company with offices in Canada and India has announced that they are launching new web-based, self-managing, clinical trial software that amongst other things will be able to extend patient Registry information into individual patient case studies and aggregate the data with comparisons to cohorts. The company has so far specifically focused their...
ROCKVILLE, Md., Dec. 10, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Jonathon Glass, MD, Director of the Emory ALS Center, presented new data from the Phase I trial of Neuralstem's human spinal cord stem cells, NSI-566, in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at the International Symposium on ALS/MND in Chicago, sponsored by the Motor Neurone Disease Association. In a Thursday presentation, "RESULTS OF PHASE 1 TRIAL OF SPINAL CORD...
University of Sheffield In research published in the journal Acta Biomaterialia, researchers from the University of Sheffield describe a new method for producing membranes to help in the grafting of stem cells onto the eye, mimicking structural features of the eye itself. The technology has been designed to treat damage to the cornea, the transparent layer on the front of the eye, which is one of the major causes of blindness in the world. Using a combination of techniques known as...
GULF SHORES, Ala., Dec. 4, 2012 /PRNewswire/ -- More than 75 percent of amyotrophic lateral sclerosis (ALS) patients who received neural reprogrammed stem cell therapy have shown a positive response to the procedure. The groundbreaking technique was introduced to the United States this year by Precision StemCell (http://www.precisionstemcell.com), an outpatient imaging and image-guided treatment facility located in Gulf Shores, Ala. The procedure is performed by Dr. Jason R....
As part of the European study TRANSEURO, five patients with Parkinson's disease will undergo brain cell transplants at Skåne University Hospital in Lund, Sweden, in early 2013. These are the first operations of their kind in Europe for over 10 years. The TRANSEURO study, which in Sweden is led by Lund University, is now taking a critical approach to the viability of cell therapy as a future treatment for Parkinson's disease. Can we replace cells that die as a result of our most common...
University of Toronto Study moves scientists 1 step closer to creating youthful heart patches from old cells A new method of growing cardiac tissue is teaching old stem cells new tricks. The discovery, which transforms aged stem cells into cells that function like much younger ones, may one day enable scientists to grow cardiac patches for damaged or diseased hearts from a patient's own stem cells—no matter what age the patient—while avoiding the threat of rejection. Stem cell...
SAN DIEGO, Nov. 27, 2012 /PRNewswire/ -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the initiation of a randomized, controlled, Phase 2 multi-center study of its investigational hematopoietic stem cell therapy, ProHema, in adult patients undergoing double umbilical cord blood transplantation (dUCBT) for hematologic malignancy. The advancement of ProHema into later-stage development...
PHILADELPHIA, Nov. 26, 2012 /PRNewswire/ -- RRY Publications LLC today announced that the use of stem cell therapies in 2012 significantly exceeded forecasts which were originally presented at the February 2012 New York Stem Cell Summit. Said Robin Young, stem cell industry analyst and host of the New York meeting: "The range and scope of stem cell therapeutic use in the United States grew much faster than we'd forecasted earlier this year. Virtually all of the increases we're...
